Huelskamp Michael D, Duesing Helena, Lefering Rolf, Raschke Michael J, Rosslenbroich Steffen
Department for Trauma-, Hand- and Reconstructive Surgery, University Hospital Münster, Münster, Germany.
Institute for Research in Operative Medicine (IFOM), University Witten/Herdecke, Cologne, Germany.
Eur J Trauma Emerg Surg. 2025 Jan 24;51(1):55. doi: 10.1007/s00068-024-02756-9.
Severe thorax trauma including multiple rib fractures and flail chest deformity are leading causes of death in trauma patients. Increasing evidence supports the use of surgical stabilisation of rib fractures (SSRF) in these patients. However, there is currently a paucity of evidence for its use in non-ventilator-dependent patients.
A retrospective propensity-matched analysis of the data of the TraumaRegister DGU for non-ventilator-dependent patients with severe rib injury (abbreviated injury score ≥ 3) was performed. Subgroup analyses with respect to injury severity score, American society of anaesthesiologists physical status classification and age were performed. Furthermore, the effect of time to surgery was analysed.
TR-DGU project ID 2023-007; ClinicalTrials.gov protocol ID: NCT06464289.
SSRF led to reduced mortality compared to conservative treatment (1.6% vs. 4.8%; p = 0.002) and in comparison to the mortality prognosis of the revised injury severity classification II (RISC II) of 5.2%. Interestingly, SSRF was associated with increased length of hospital and intensive care unit stay, higher rates of organ failure and secondary intubation. The patients with organ failure received SSRF later than those without organ failure.
Here we report on the largest currently published dataset of non-intubated patients receiving SSRF, which showed reduced mortality in the SSRF cohort. The data indicates that SSRF is a viable treatment option for non-intubated patients. The observed late surgical time points, which may be due to cross over after failed conservative treatment, might be the cause for the observed increased rate of organ failure.
严重胸部创伤,包括多根肋骨骨折和连枷胸畸形,是创伤患者死亡的主要原因。越来越多的证据支持对这些患者使用肋骨骨折手术固定术(SSRF)。然而,目前其在非呼吸机依赖患者中的应用证据不足。
对创伤注册数据库DGU中严重肋骨损伤(简明损伤评分≥3)的非呼吸机依赖患者的数据进行回顾性倾向匹配分析。对损伤严重程度评分、美国麻醉医师协会身体状况分类和年龄进行亚组分析。此外,分析了手术时间的影响。
TR-DGU项目ID 2023-007;ClinicalTrials.gov方案ID:NCT06464289。
与保守治疗相比,SSRF导致死亡率降低(1.6%对4.8%;p = 0.002),与修订的损伤严重程度分类II(RISC II)的5.2%的死亡率预后相比也是如此。有趣的是,SSRF与住院时间和重症监护病房停留时间延长、器官衰竭发生率和二次插管率升高有关。发生器官衰竭的患者比未发生器官衰竭的患者接受SSRF的时间更晚。
在此,我们报告了目前已发表的接受SSRF的非插管患者的最大数据集,该数据集显示SSRF队列中的死亡率降低。数据表明,SSRF是一种适用于非插管患者的可行治疗选择。观察到的手术时间较晚,这可能是由于保守治疗失败后的交叉治疗所致,可能是观察到器官衰竭发生率增加的原因。